Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
J Gastroenterol Hepatol. 2010 Jan;25(1):183-93. doi: 10.1111/j.1440-1746.2009.06024.x. Epub 2009 Nov 19.
The prevalence and incidence of inflammatory bowel disease (IBD) differs worldwide. While the prevalence of IBD has stabilized in Europe, the USA and Japan, an increasing trend has been observed in Asia. However, there are no data on the current clinical practice for the management of IBD in the region. The present study aims to investigate the number of existing and new cases of IBD and to understand the current practice of diagnosis and treatment of IBD in different Asian countries.
A self-administered questionnaire, designed according to European and US guidelines, was distributed to IBD specialists throughout Asia. The questionnaire estimated the annual incidence of existing and new IBD cases in physicians' clinical practices and evaluated their procedures of diagnosis and preference for therapeutic treatment and maintenance treatment.
Eighty-seven questionnaires were received out of the 107 distributed. In the clinical practices of these 87 respondents, there were 502 existing and 73 new cases per year for ulcerative colitis (UC) and 202 existing and 32 new cases per year for Crohn's disease (CD). Colonoscopy and histology were the most commonly used methods for the diagnosis of UC and CD, but clinical practice regarding the diagnosis of IBD varied. The treatment of choice for mild-to-moderate UC and CD was 5-aminosalicylic acid (5-ASA), which is also the preferred choice for the maintenance treatment of UC and CD.
Clinical practice with regards to IBD diagnosis and management varies within Asia.5-ASA is the preferred treatment and maintenance therapy for mild-to-moderate IBD.
炎症性肠病(IBD)在世界范围内的流行率和发病率不同。虽然欧洲、美国和日本的 IBD 流行率已经稳定,但亚洲的发病率呈上升趋势。然而,该地区目前还没有关于 IBD 管理的临床实践的数据。本研究旨在调查 IBD 现有和新发病例的数量,并了解不同亚洲国家 IBD 的诊断和治疗现状。
根据欧洲和美国的指南设计了一份自我管理问卷,并分发给亚洲各地的 IBD 专家。该问卷估计了医生临床实践中 IBD 现有和新发病例的年发生率,并评估了他们的诊断程序以及对治疗和维持治疗的偏好。
在分发的 107 份问卷中,收到了 87 份。在这 87 位受访者的临床实践中,溃疡性结肠炎(UC)每年有 502 例现有病例和 73 例新病例,克罗恩病(CD)每年有 202 例现有病例和 32 例新病例。结肠镜检查和组织学是 UC 和 CD 诊断最常用的方法,但 IBD 的诊断实践存在差异。轻中度 UC 和 CD 的治疗选择是 5-氨基水杨酸(5-ASA),它也是 UC 和 CD 维持治疗的首选。
亚洲内部在 IBD 的诊断和管理方面存在差异。5-ASA 是轻中度 IBD 的首选治疗和维持治疗药物。